Vericel Corporation (ATQP)
XFRA 
Summary
ATQP Chart
Vericel Q1 Earnings Call Highlights
Vericel NASDAQ: VCEL reported record first-quarter revenue and raised its full-year 2026 outlook, citing strong growth across its MACI cartilage repair franchise and Burn Care business, as well as expected NexoBrid procurement revenue from a new federal contract.
Vericel Corporation (VCEL) Q1 2026 Earnings Call Transcript
Vericel Corporation (VCEL) Q1 2026 Earnings Call Transcript
Vericel Corporation (VCEL) Reports Q1 Loss, Beats Revenue Estimates
Vericel Corporation (VCEL) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to a loss of $0.23 per share a year ago.
Vericel Corporation (ATQP) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Vericel Corporation ever had a stock split?
Vericel Corporation Profile
| Biotechnology Industry | Healthcare Sector | Dominick C. Colangelo CEO | XFRA Exchange | US92346J1088 ISIN |
| US Country | 357 Employees | - Last Dividend | 18 Feb 2010 Last Split | 4 Feb 1997 IPO Date |
Overview
Vericel Corporation is a commercial-stage biopharmaceutical company dedicated to innovating cellular therapies for the sports medicine and severe burn care markets within the United States. Originating from its foundation in 1989 and previously known as Aastrom Biosciences, Inc., the company has grown its footprint in the therapeutic landscape, focusing on delivering transformative treatments. With its headquarters in Cambridge, Massachusetts, Vericel Corporation is at the forefront of cellular therapy research, development, manufacture, and distribution, aiming to address significant unmet medical needs in its chosen markets.
Products and Services
- MACI
MACI represents an innovative autologous cultured chondrocytes product, presented on a porcine collagen membrane. It is targeted at the repair of symptomatic, single, or multiple full-thickness cartilage defects of the knee. This cell therapy innovation aims to facilitate the natural regeneration process of the knee cartilage, offering a sophisticated solution to individuals struggling with knee cartilage issues.
- Epicel
Epicel is a permanent skin replacement humanitarian use device, designed for the treatment of adult and pediatric patients suffering from deep-dermal or full-thickness burns. This product marks a significant advancement in severe burn care, providing a critical solution for patients in need of extensive skin repair and replacement, marking a pivotal achievement in the field of regenerative medicine.
- NexoBrid
NexoBrid, currently in its preapproval stage, is a biological orphan product formulated for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. It represents Vericel Corporation's ongoing commitment to addressing the needs of burn victims through cutting-edge biological treatments, providing a new avenue for burn care that prioritizes efficient eschar removal without the need for extensive surgical intervention.
